Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma Inc. announced its third quarter 2026 financial results and provided an operational update on BB-301, its gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD). Interim clinical data shows durable and improving responses in patients treated with low and high doses of BB-301, with no severe adverse events. The compan…